Skip to main content
. Author manuscript; available in PMC: 2020 Nov 14.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2020 Apr 20;23(4):661–669. doi: 10.1038/s41391-020-0229-z

Fig. 4.

Fig. 4

The differential expression of YAP1 in PCa. (A) The expression of YAP1 in LuCaP PDXs. The expression levels of YAP1, TAZ, AR, and NEPC markers (FOXA2, SOX2, CHGA, and SYP) were extracted from RNAseq data derived from 46 LuCaP PDXs including (from left to right) AR+/NE− (group 1, n=35), ARlow/NE− (group 2, n=1), AR−/NE− (group 3, n=1), AR+/NE+ (group 4, n=1), and AR−/NE+ tumors (group 5, n=8). YAP1 expression was lost in all the NE positive LuCaP PDXs. Whereas, YAP1 was expressed in all but one prostate adenocarcinoma cases. (B - F) Expression of YAP1 in CRPC vs NEPC. The mRNA levels of YAP1 were extracted from RNA-seq/RNA microarray data of Neuroendocrine Prostate Cancer. The levels of YAP1 was decreased in NEPC. (G) Heatmap of differentially expressed genes in PCa cell lines. The mRNA levels of YAP1, TAZ, and NEPC markers (CHGA, SYP, SOX2, and FOXA2) were extracted from RNA-seq data of Cancer Cell Line Encyclopedia. The mRNA level of YAP1 was the lowest in NEPC H660 cells. But TAZ displayed no consistent patterns among PCa cell lines. (H) Western blot in assessing the protein levels of YAP1 in PCa cell lines. Lower panel is the quantification of Western blot result.